Funding News
India's ₹10,000 Crore Fund of Funds 2.0 Has Opened a Specific Runway for Healthtech and MedTech — This Is the Domestic Capital Shift That Healthcare Founders Have Been Waiting For
By Mustafa Shariff, Editor in Chief · April 22,2026 · 5 min read
Summary
- India's ₹10,000 Crore Fund of Funds 2.0 and What It Means for Healthtech and MedTech Founders
- India's Fund of Funds 2.0 has opened a ₹10,000 crore pathway for SEBI-registered AIFs investing in healthtech, MedTech, and deep tech. Here is what it means for India's healthcare startup ecosystem.
India's healthcare startup ecosystem has a structural funding problem that has persisted throughout the past decade. Foreign venture capital — from Sequoia, General Catalyst, SoftBank, Tiger Global, and a handful of Singapore and US-based healthcare specialists — has been the dominant source of growth capital for Indian healthtech companies. Domestic institutional capital flows into healthcare innovation have been minimal, creating a dependence on international investor appetites that leave India's healthcare startup ecosystem exposed to global funding cycle volatility.
The ₹10,000 crore Fund of Funds 2.0, launched through Startup India under the DPIIT, targets SEBI-registered Alternative Investment Funds backing startups in priority areas including deep tech, early-stage ventures, and technology-driven manufacturing. Healthcare is explicitly identified as a priority sector — covering AI-powered diagnostics, medical devices, digital health platforms, genomics tools, drug discovery technology, and hospital management systems. The FoF 2.0 builds on the original Fund of Funds launched in 2016, adding a Venture Capital Investment Committee of startup ecosystem veterans to screen AIFs and co-investment provisions that can amplify the capital available to healthcare-focused funds.
Why Healthcare Was Underrepresented in Earlier Institutional Funding
The absence of domestic institutional capital in India's healthcare startup funding has specific structural causes. Indian insurance companies and pension funds — the institutional investors who anchor venture fund LPs in the US and Europe — operate under regulatory frameworks that constrained investment in unlisted securities and alternative assets. Healthcare venture investing requires long time horizons (clinical validation, regulatory approval, and hospital adoption cycles are all slow) that conflict with the return timeline expectations of most domestic institutional investors. And the healthcare startup ecosystem in India, while growing rapidly, lacked the track record of successful exits that builds domestic institutional confidence.
The FoF 2.0 addresses these constraints by interposing a government-backed vehicle between institutional capital and startup investing, providing the AAA credit quality that Indian insurance and pension fund LPs require while directing that capital toward AIFs with the domain expertise to evaluate healthcare investments.
The Priority Healthcare Segments
The segments identified as healthcare priorities within FoF 2.0 align precisely with where India's innovation pipeline is most active. AI-powered diagnostics — where Qure.ai, Niramai, DeepTek, and a dozen emerging companies have built globally competitive products. Medical devices — where India's domestic MedTech sector has been growing rapidly but historically attracted limited domestic venture funding. Digital health platforms — the broadest and most diverse category, covering everything from telemedicine to hospital EHR to insurance technology. Genomics — where MedGenome, 4baseCare, and emerging precision medicine startups have demonstrated India's scientific capability. And drug discovery tools — where the Biopharma SHAKTI mission's ambitions require a commercial startup ecosystem alongside public research infrastructure.
What This Means for BHC Founders
For healthcare founders in the BHC ecosystem, the FoF 2.0 has two immediate practical implications. First, it increases the number of domestically-funded AIFs available as investor options — reducing the dependence on the small number of India-focused foreign VCs that have historically dominated early-stage healthcare funding in India. Second, it signals a sustained government commitment to building domestic healthcare innovation capital that will compound over time as the FoF's AIF investments produce exits and return capital.
The co-investment provisions are particularly significant: government co-investment alongside private AIFs in individual healthcare startups reduces the risk profile for private investors while providing companies with a government-associated investor whose network and policy access add non-financial value.
BHC Perspective
At Bengaluru Health Community, the FoF 2.0 is the structural capital story we have been watching for. India's healthcare innovation ecosystem has world-class founders, world-class clinical partnerships through our hospital networks, and world-class research institutions. The missing piece has been deep, patient domestic capital that can fund the 5-10 year journeys that clinical AI, medical devices, and drug discovery startups require. FoF 2.0 is a meaningful step toward building that capital ecosystem.
Frequently Asked Questions
Q: What is India's Fund of Funds 2.0?
A: A ₹10,000 crore government fund investing in SEBI-registered AIFs that back Indian startups in priority sectors including deep tech, early-stage ventures, and technology-driven manufacturing. Healthcare is explicitly a priority sector.
Q: Which healthcare segments does FoF 2.0 target?
A: AI-powered diagnostics, medical devices, digital health platforms, genomics tools, drug discovery technology, and hospital management systems — segments where India has demonstrated innovation potential but historically struggled to attract domestic institutional capital.
Q: How does FoF 2.0 differ from the original Fund of Funds?
A: FoF 2.0 adds a Venture Capital Investment Committee of ecosystem veterans to screen AIFs, co-investment provisions that amplify capital available to healthcare-focused funds, and explicit priority sector designations including healthcare — building on the original 2016 FoF.